<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39323472</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2296-858X</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Frontiers in medicine</Title><ISOAbbreviation>Front Med (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Structural and genomic evolutionary dynamics of Omicron variant of SARS-CoV-2 circulating in Madhya Pradesh, India.</ArticleTitle><Pagination><StartPage>1416006</StartPage><MedlinePgn>1416006</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1416006</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fmed.2024.1416006</ELocationID><Abstract><AbstractText>The SARS-CoV-2 Omicron (B.1.1.529) variant emerged in early November 2021 and its rapid spread created fear worldwide. This was attributed to its increased infectivity and escaping immune mechanisms. The spike protein of Omicron has more mutations (&gt;30) than any other previous variants and was declared as the variant of concern (VOC) by the WHO. The concern among the scientific community was huge about this variant, and a piece of updated information on circulating viral strains is important in order to better understand the epidemiology, virus pathogenicity, transmission, therapeutic interventions, and vaccine development. A total of 710 samples were processed for sequencing and identification up to a resolution of sub-lineage. The sequence analysis revealed Omicron variant with distribution as follows: B.1.1, B.1.1.529, BA.1, BA.2, BA.2.10, BA.2.10.1, BA.2.23, BA.2.37, BA.2.38, BA.2.43, BA.2.74, BA.2.75, BA.2.76, and BA.4 sub-lineages. There is a shift noted in circulating lineage from BA.1 to BA.2 to BA.4 over a period from January to September 2022. Multiple signature mutations were identified in S protein T376A, D405N, and R408S mutations, which were new and common to all BA.2 variants. Additionally, R346T was seen in emerging BA.2.74 and BA.2.76 variants. The emerging BA.4 retained the common T376A, D405N, and R408S mutations of BA.2 along with a new mutation F486V. The samples sequenced were from different districts of Madhya Pradesh and showed a predominance of BA.2 and its variants circulating in this region. The current study identified circulation of BA.1 and BA.1.1 variants during initial phase. The predominant Delta strain of the second wave has been replaced by the Omicron variant in this region over a period of time. This study successfully deciphers the dynamics of the emergence and replacement of various sub-lineages of SARS-CoV-2 in central India on real real-time basis.</AbstractText><CopyrightInformation>Copyright © 2024 Dhankher, Yadav, Sharma, Gupta, Yadav, Dash and Parida.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dhankher</LastName><ForeName>Suman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Virology Division, Defence Research and Development Establishment, Gwalior, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yadav</LastName><ForeName>Pooja</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Virology Division, Defence Research and Development Establishment, Gwalior, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Shashi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Virology Division, Defence Research and Development Establishment, Gwalior, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gupta</LastName><ForeName>Ekta</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Virology Division, Defence Research and Development Establishment, Gwalior, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yadav</LastName><ForeName>Ram Govind</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Virology Division, Defence Research and Development Establishment, Gwalior, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dash</LastName><ForeName>Paban Kumar</ForeName><Initials>PK</Initials><AffiliationInfo><Affiliation>Virology Division, Defence Research and Development Establishment, Gwalior, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parida</LastName><ForeName>Manmohan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Virology Division, Defence Research and Development Establishment, Gwalior, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Med (Lausanne)</MedlineTA><NlmUniqueID>101648047</NlmUniqueID><ISSNLinking>2296-858X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BA.2</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Genome</Keyword><Keyword MajorTopicYN="N">Lineage</Keyword><Keyword MajorTopicYN="N">NGS</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>4</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39323472</ArticleId><ArticleId IdType="pmc">PMC11422100</ArticleId><ArticleId IdType="doi">10.3389/fmed.2024.1416006</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (WHO) . WHO coronavirus (COVID-19) dashboard. Available at:
https://covid19.who.int/ (Accessed February 20, 2024).</Citation></Reference><Reference><Citation>Ren SY, Wang WB, Gao RD, Zhou AM. Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance. World J Clin Cases. (2022) 10:1–11. doi: 10.12998/wjcc.v10.i1.1, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v10.i1.1</ArticleId><ArticleId IdType="pmc">PMC8727245</ArticleId><ArticleId IdType="pubmed">35071500</ArticleId></ArticleIdList></Reference><Reference><Citation>He X, Hong W, Pan X, Lu G, Wei X. SARS-CoV-2 Omicron variant: characteristics and prevention. MedComm. (2021) 2:838–45. doi: 10.1002/mco2.110</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.110</ArticleId><ArticleId IdType="pmc">PMC8693031</ArticleId><ArticleId IdType="pubmed">34957469</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M, Krüger N, Schulz S, Cossmann A, Rocha C, Kempf A, et al. . The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. (2022) 185:447–456.e11. doi: 10.1016/j.cell.2021.12.032, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.032</ArticleId><ArticleId IdType="pmc">PMC8702401</ArticleId><ArticleId IdType="pubmed">35026151</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakur V, Ratho RK. OMICRON (B.1.1.529): a new SARS‐CoV‐2 variant of concern mounting worldwide fear. J Med Virol. (2022) 94:1821–4. doi: 10.1002/jmv.27541</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27541</ArticleId><ArticleId IdType="pubmed">34936120</ArticleId></ArticleIdList></Reference><Reference><Citation>Lou F, Li M, Pang Z, Jiang L, Guan L, Tian L, et al. . Understanding the secret of SARS-CoV-2 variants of concern/interest and immune escape. Front Immunol. (2021) 12:744242. doi: 10.3389/fimmu.2021.744242, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.744242</ArticleId><ArticleId IdType="pmc">PMC8602852</ArticleId><ArticleId IdType="pubmed">34804024</ArticleId></ArticleIdList></Reference><Reference><Citation>Meo SA, Meo AS, Al-Jassir FF, Klonoff DC. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci. (2021) 25:8012–8. doi: 10.26355/eurrev_202112_27652</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202112_27652</ArticleId><ArticleId IdType="pubmed">34982465</ArticleId></ArticleIdList></Reference><Reference><Citation>Popovic ME. XBB.1.5 Kraken cracked: Gibbs energies of binding and biosynthesis of the XBB.1.5 variant of SARS-CoV-2. Microbiol Res. (2023) 270:127337. doi: 10.1016/j.micres.2023.127337</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micres.2023.127337</ArticleId><ArticleId IdType="pmc">PMC9928726</ArticleId><ArticleId IdType="pubmed">36804126</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunadi, Wibawa H, Hakim MS, Marcellus, Trisnawati I, Khair RE, et al. . Molecular epidemiology of SARS-CoV-2 isolated from COVID-19 family clusters. BMC Med Genet. (2021) 14:144. doi: 10.1186/s12920-021-00990-3, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12920-021-00990-3</ArticleId><ArticleId IdType="pmc">PMC8169432</ArticleId><ArticleId IdType="pubmed">34074255</ArticleId></ArticleIdList></Reference><Reference><Citation>Karyakarte R, Das R, Dudhate S, Agarasen J, Pillai P, Chandankhede P, et al. . Clinical characteristics and outcomes of laboratory-confirmed SARS-CoV-2 cases infected with Omicron subvariants and XBB recombinant variant. Cureus. (2023) 15:e35261. doi: 10.1101/2023.01.05.23284211</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2023.01.05.23284211</ArticleId><ArticleId IdType="pmc">PMC10035460</ArticleId><ArticleId IdType="pubmed">36968876</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovanetti M, Benedetti F, Campisi G, Ciccozzi A, Fabris S, Ceccarelli G, et al. . Evolution patterns of SARS-CoV-2: snapshot on its genome variants. Biochem Biophys Res Commun. (2021) 538:88–91. doi: 10.1016/j.bbrc.2020.10.102, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.10.102</ArticleId><ArticleId IdType="pmc">PMC7836704</ArticleId><ArticleId IdType="pubmed">33199021</ArticleId></ArticleIdList></Reference><Reference><Citation>Popovic M. Never ending story? Evolution of SARS-CoV-2 monitored through Gibbs energies of biosynthesis and antigen-receptor binding of Omicron BQ.1, BQ.1.1, XBB and XBB.1 variants. Microb Risk Anal. (2023) 23:100250. doi: 10.1016/j.mran.2023.100250</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mran.2023.100250</ArticleId><ArticleId IdType="pmc">PMC9896887</ArticleId><ArticleId IdType="pubmed">36777740</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaman K, Shete AM, Mishra SK, Kumar A, Reddy MM, Sahay RM, et al. . Omicron BA.2 lineage predominance in severe acute respiratory syndrome coronavirus 2 positive cases during the third wave in North India. Front Med. (2022) 9:955930. doi: 10.3389/fmed.2022.955930</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.955930</ArticleId><ArticleId IdType="pmc">PMC9666497</ArticleId><ArticleId IdType="pubmed">36405589</ArticleId></ArticleIdList></Reference><Reference><Citation>Araf Y, Akter F, Tang YD, Fatemi R, MSA P, Zheng C, et al. . Omicron variant of SARS‐CoV‐2: genomics, transmissibility, and responses to current COVID‐19 vaccines. J Med Virol. (2022) 94:1825–32. doi: 10.1002/jmv.27588</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27588</ArticleId><ArticleId IdType="pmc">PMC9015557</ArticleId><ArticleId IdType="pubmed">35023191</ArticleId></ArticleIdList></Reference><Reference><Citation>Callaway E. Heavily mutated Omicron variant puts scientists on alert. Nature. (2021) 600:21. doi: 10.1038/d41586-021-03552-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-03552-w</ArticleId><ArticleId IdType="pubmed">34824381</ArticleId></ArticleIdList></Reference><Reference><Citation>Brandolini M, Gatti G, Grumiro L, Zannoli S, Arfilli V, Cricca M, et al. . Omicron sub-lineage BA.5 and recombinant XBB evasion from antibody neutralisation in BNT162b2 vaccine recipients. Microorganisms. (2023) 11:191. doi: 10.3390/microorganisms11010191, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11010191</ArticleId><ArticleId IdType="pmc">PMC9866687</ArticleId><ArticleId IdType="pubmed">36677483</ArticleId></ArticleIdList></Reference><Reference><Citation>Lea Vikse E, Sekse Erdal M, Hungnes O, Bragstad K. Poor neutralizing antibody responses against SARS-CoV-2 Omicron BQ.1.1 and XBB in Norway in October 2022. Influenza Other Respir Viruses. (2023) 17:e13144. doi: 10.1111/irv.13144</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13144</ArticleId><ArticleId IdType="pmc">PMC10236499</ArticleId><ArticleId IdType="pubmed">37273461</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendiola-Pastrana IR, López-Ortiz E, de la Loza-Zamora JG R, González J, Gómez-García A, López-Ortiz G. SARS-CoV-2 variants and clinical outcomes: a systematic review. Life. (2022) 12:170. doi: 10.3390/life12020170</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12020170</ArticleId><ArticleId IdType="pmc">PMC8879159</ArticleId><ArticleId IdType="pubmed">35207458</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L, Wing-Yee Mok B, Chen LL, Man-Chun Chan J, Tak-Yin Tsang O, Hoi-Shiu Lam B, et al. . Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or CoronaVac vaccine recipients. Clin Infect Dis. (2022) 75:e822–6. doi: 10.1093/cid/ciab1041</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab1041</ArticleId><ArticleId IdType="pmc">PMC8754807</ArticleId><ArticleId IdType="pubmed">34915551</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferré VM, Peiffer-Smadja N, Visseaux B, Descamps D, Ghosn J, Charpentier C. Omicron SARS-CoV-2 variant: what we know and what we don’t. Anaesth Crit Care Pain Med. (2022):41: 100998. doi: 10.1016/j.accpm.2021.100998</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.accpm.2021.100998</ArticleId><ArticleId IdType="pmc">PMC8660660</ArticleId><ArticleId IdType="pubmed">34902630</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyson JR, James P, Stoddart D, Sparks N, Wickenhagen A, Hall G, et al. . (2020) Improvements to the ARTIC multiplex PCR method for SARS-CoV-2 genome sequencing using nanopore. bioRxiv. Available at: http://www.ncbi.nlm.nih.gov/pubmed/32908977. [Epub ahead of preprint]</Citation></Reference><Reference><Citation>Liu H, Li J, Lin Y, Bo X, Song H, Li K, et al. . Assessment of two-pool multiplex long-amplicon nanopore sequencing of SARS-CoV-2. J Med Virol. (2022) 94:327–34. doi: 10.1002/jmv.27336, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27336</ArticleId><ArticleId IdType="pmc">PMC8662006</ArticleId><ArticleId IdType="pubmed">34524690</ArticleId></ArticleIdList></Reference><Reference><Citation>Genotypic Technology Pvt. Ltd. 
Commander, a command line free GuI-based sequencing data analysis tool developed by Genotypic Technology, Bangalore India. (2023). Available at:
https://www.genotypic.co.in/commander/. (Accessed July 23, 2023)</Citation></Reference><Reference><Citation>Yadav PD, Nyayanit DA, Majumdar T, Patil S, Kaur H, Gupta N, et al. . An epidemiological analysis of SARS-CoV-2 genomic sequences from different regions of India. Viruses. (2021) 13:925. doi: 10.3390/v13050925, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13050925</ArticleId><ArticleId IdType="pmc">PMC8156686</ArticleId><ArticleId IdType="pubmed">34067745</ArticleId></ArticleIdList></Reference><Reference><Citation>Maitra A, Raghav S, Dalal A, Ali F, Paynter VM, Paul D, et al. . (2020). bioRxiv. Available at: 10.1101/2020.08.03.233718. [Epub ahead of preprint]</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.08.03.233718</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Bansal K. Cross-sectional genomic perspective of epidemic waves of SARS-CoV-2: a pan India study. Virus Res. (2022) 308:198642. doi: 10.1016/j.virusres.2021.198642, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2021.198642</ArticleId><ArticleId IdType="pmc">PMC8606321</ArticleId><ArticleId IdType="pubmed">34822953</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal K, Kumar S. Mutational cascade of SARS-CoV-2 leading to evolution and emergence of Omicron variant. Virus Res. (2022) 315:198765. doi: 10.1016/j.virusres.2022.198765, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2022.198765</ArticleId><ArticleId IdType="pmc">PMC8968180</ArticleId><ArticleId IdType="pubmed">35367284</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung C, Kmiec D, Koepke L, Zech F, Jacob T, Sparrer KMJ, et al. . Omicron: what makes the latest SARS-CoV-2 variant of concern so concerning? J Virol. (2022) 96:e0207721. doi: 10.1128/jvi.02077-21, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.02077-21</ArticleId><ArticleId IdType="pmc">PMC8941872</ArticleId><ArticleId IdType="pubmed">35225672</ArticleId></ArticleIdList></Reference><Reference><Citation>El Mazouri S, Essabbar A, Aanniz T, Eljaoudi R, Belyamani L, Ibrahimi A, et al. . Genetic diversity and evolutionary dynamics of the Omicron variant of SARS-CoV-2 in Morocco. Pathog Glob Health. (2024) 118:241–52. doi: 10.1080/20477724.2023.2250942, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/20477724.2023.2250942</ArticleId><ArticleId IdType="pmc">PMC11221468</ArticleId><ArticleId IdType="pubmed">37635364</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu W, Huang Z, Xiao J, Wu Y, Xia N, Yuan Q. Evolution of the SARS-CoV-2 Omicron variants: genetic impact on viral fitness. Viruses. (2024) 16:184. doi: 10.3390/v16020184, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v16020184</ArticleId><ArticleId IdType="pmc">PMC10893260</ArticleId><ArticleId IdType="pubmed">38399960</ArticleId></ArticleIdList></Reference><Reference><Citation>Markov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI, et al. . The evolution of SARS-CoV-2. Nat Rev Microbiol. (2023) 21:361–79. doi: 10.1038/s41579-023-00878-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00878-2</ArticleId><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Eales O, de Oliveira Martins L, Page AJ, Wang H, Bodinier B, Tang D, et al. . Dynamics of competing SARS-CoV-2 variants during the Omicron epidemic in England. Nat Commun. (2022) 13:4375. doi: 10.1038/s41467-022-32096-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32096-4</ArticleId><ArticleId IdType="pmc">PMC9330949</ArticleId><ArticleId IdType="pubmed">35902613</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>